A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use. Potential immunomodulatory, antiinflammatory, anti-angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma. Through an increase in the degradation of TNFα-mRNA, thalidomide reduces the production of TNFα by monocytes and macrophages stimulated by lipopolysaccharide or by T lymphocytes induced by mitogenic stimuli. The decreased level of TNFα alters the mechanisms of intracellular transduction by preventing the activation of NF-kB and by decreasing the synthesis of proteins, in particular IL-6, involved in cell proliferation, inflammation, angiogenesis and protection from apoptosis. Furthermore, thalidomide affects VEGF levels by down-regulating its expression. Nowadays, new safer and less toxic drugs, analogs of thalidomide, are emerging as beneficial for a more targeted treatment of multiple myeloma and several other diseases such as Crohn';s disease, rheumatoid arthritis, sarcoidosis, erythema nodosum leprosum, graft-versus-host disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 1×
“MM is a malignant disease affecting senior adults and characterized by the proliferation and accumulation of B lymphocytes and plasma cells in the bone marrow, and by an increased production of monoclonal protein detectable in serum and/or urine [13].”
BackgroundLopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.001 · Cited by 188 · cited 1×
“Ck1-α has a role in the biology of DEL(5q) MDS (Myelodysplastic syndrome) [74] and it is a therapeutic target in myeloid malignancies [75].”
BackgroundMuller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Järås, M., Miller, P. G., Chu, L. P., Puram, R. V., Fink, E. C., Schneider, R. K., Al-Shahrour, F., Peña, P., Breyfogle, L. J., Hartwell, K. A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131033 · Cited by 92
Cited by
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Metadata
- Authors
- Mercurio, A., Adriani, G., Catalano, A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-09-14
- Volume
- 24
- Issue
- 25
- Pages
- 2736-2744
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2621183612
- Cited by
- 81
- References
- 8
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. https://app.cochat.ai/papers/10.2174/0929867324666170601074646
- The paper
- Mercurio, A., Adriani, G., Catalano, A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017). A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. Current Medicinal Chemistry. https://doi.org/10.2174/0929867324666170601074646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.